SUD.ASX
SUDA Pharmaceuticals receives TGA approval for ZolpiMist adult insomnia treatment
Perth-based SUDA Pharmaceuticals (ASX: SUD) has received approval from the Therapeutic Goods Administration for its ZolpiMist oral spray to be used in the treatment of short-term adult insomnia. The company has also been approved as a supplemental active pharmaceutical ingredient (API) supplier and final product manufacturer, allowing it to supply ZolpiMist at a more competitive […]
Suda Pharmaceuticals to co-develop paediatric consumer market product with Laboratorios Ordesa
A novel product for the consumer paediatric market could soon be developed after drug delivery specialist Suda Pharmaceuticals (ASX: SUD) announced a fully-funded feasibility study and option agreement with Spanish pharmaceutical company Laboratorios Ordesa. The deal was agreed in lieu of Suda’s new chief executive officer Dr Michael Baker taking the reigns of the company early […]
SUDA Pharmaceuticals inks deal with Cann Pharmaceutical to develop medical cannabis oral spray
Drug delivery specialist SUDA Pharmaceuticals (ASX: SUD) has finalised a deal with medical cannabis company Cann Pharmaceutical Australia that will see the pair develop an oro-mucosal spray to treat drug-resistant epilepsy, melanoma and motion sickness. The Perth-based company today announced the finalised product development, licence and supply agreement, which follows a binding term sheet signed […]
SUDA signs licensing deal with Mitsubishi Tanabe Pharma for Asian sales of ZolpiMist
Perth-based SUDA Pharmaceuticals (ASX: SUD) has entered into an exclusive licence agreement with Mitsubishi Tanabe Pharma Singapore Pte Ltd for sales of its ZolpiMist anti-insomnia oral spray in the Asian market. The supply and distribution agreement, which includes an option period of 12 months, will commence with Singapore, Malaysia and the Philippines and extend into […]